Anticoagulation management during extracorporeal membrane oxygenation - a mini-review

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109957" target="_blank" >RIV/00843989:_____/22:E0109957 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/22:A2302JED

Result on the web

<a href="https://www.mdpi.com/1648-9144/58/12/1783" target="_blank" >https://www.mdpi.com/1648-9144/58/12/1783</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/medicina58121783" target="_blank" >10.3390/medicina58121783</a>

Result language

angličtina

Original language name

Anticoagulation management during extracorporeal membrane oxygenation - a mini-review

Original language description

Extracorporeal membrane oxygenation (ECMO) has been established as a life-saving technique for patients with the most severe forms of respiratory or cardiac failure. It can, however, be associated with severe complications. Anticoagulation therapy is required to prevent ECMO circuit thrombosis. It is, however, associated with an increased risk of hemocoagulation disorders. Thus, safe anticoagulation is a cornerstone of ECMO therapy. The most frequently used anticoagulant is unfractionated heparin, which can, however, cause significant adverse effects. Novel drugs (e.g., argatroban and bivalirudin) may be superior to heparin in the better predictability of their effects, functioning independently of antithrombin, inhibiting thrombin bound to fibrin, and eliminating heparin-induced thrombocytopenia. It is also necessary to keep in mind that hemocoagulation tests are not specific, and their results, used for setting up the dosage, can be biased by many factors. The knowledge of the advantages and disadvantages of particular drugs, limitations of particular tests, and individualization are cornerstones of prevention against critical events, such as life-threatening bleeding or acute oxygenator failure followed by life-threatening hypoxemia and hemodynamic deterioration. This paper describes the effects of anticoagulant drugs used in ECMO and their monitoring, highlighting specific conditions and factors that might influence coagulation and anticoagulation measurements.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30221 - Critical care medicine and Emergency medicine

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Medicina

ISSN

1010-660X

e-ISSN

1648-9144

Volume of the periodical

58

Issue of the periodical within the volume

12

Country of publishing house

CH - SWITZERLAND

Number of pages

15

Pages from-to

1-15

UT code for WoS article

000902698100001

EID of the result in the Scopus database

2-s2.0-85144526748